{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10006","date":"2018-08-15T16:00:00.000Z","role":"Approver"},{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10006","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"evidence":[{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_seg_el","type":"EvidenceLine","specifiedBy":"GeneValiditySegregationEvidencCriteria","strengthScore":3},{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_ad_other_el","type":"EvidenceLine","evidence":[{"id":"cggv:48eb2872-c581-4614-9815-66d2186fbb05_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0365ad31-21eb-46f3-a4ba-f6c77e69d7a3","type":"Proband","ageType":"AgeAtDeath","ageUnit":"cggv","detectionMethod":"X-exome","firstTestingMethod":"Exome sequencing","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Whole genome shotgun sequencing","sex":"Male","variant":{"id":"cggv:48eb2872-c581-4614-9815-66d2186fbb05_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:39ec51eb-4d46-4726-af39-bb3370910566","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_006724625.2(DLG3):c.-8dup (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA642471260"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27222290","type":"dc:BibliographicResource","dc:abstract":"Intellectual disability (ID) is a clinically complex and heterogeneous disorder, which has variable severity and may be associated with additional dysmorphic, metabolic, neuromuscular or psychiatric features. Although many coding variants have been implicated in ID, identification of pathogenic non-coding regulatory variants has only been achieved in a few cases to date. We identified a duplication of a guanine on chromosome X, NC_000023.10:g.69665044dupG 7 nucleotides upstream of the translational start site in the 5' untranslated region (UTR) of the known ID gene DLG3 that encodes synapse-associated protein 102 (SAP102). The dupG variant segregated with affected status in a large multigenerational family with non-syndromic X-linked ID and was predicted to disrupt folding of the mRNA. When tested on blood cells from the affected individuals, DLG3 mRNA levels were not altered, however, DLG3/SAP102 protein levels were. We also showed by dual luciferase reporter assay that the dupG variant interfered with translation. All currently known pathogenic DLG3 variants are predicted to be null, however the dupG variant likely leads to only a modest reduction of SAP102 levels accounting for the milder phenotype seen in this family.","dc:creator":"Kumar R","dc:date":"2016","dc:title":"A non-coding variant in the 5' UTR of DLG3 attenuates protein translation to cause non-syndromic intellectual disability."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27222290","rdfs:label":"IV-1"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5,"dc:description":"no coding region, UTR \nnot impact on RNA\nreduce protein expression"}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":0.5},{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_ad_null_el","type":"EvidenceLine","evidence":[{"id":"cggv:e4cfd66d-5236-44ae-be2a-b01a84cae3af_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:a81ba55f-44f1-4f29-8db1-b40ddf93d541","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","previousTesting":true,"previousTestingDescription":"In the index patient, V-1, etiological investigations such as urine metabolic screening, karyotype analysis, Fragile-X testing, FISH on 22q11.2 locus, creatinine kinase, lactate, carnitine, very long fatty acids, EEG and brain MRI were normal.","secondTestingMethod":"Exome sequencing","sex":"Male","variant":{"id":"cggv:e4cfd66d-5236-44ae-be2a-b01a84cae3af_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:7317390c-5878-4934-9b5e-6aef56e38c81","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021120.3(DLG3):c.985+1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/127194"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24721225","type":"dc:BibliographicResource","dc:abstract":"X-linked intellectual disability (XLID) is a group of genetically heterogeneous disorders characterized by substantial impairment in cognitive abilities, social and behavioral adaptive skills. Next generation sequencing technologies have become a powerful approach for identifying molecular gene mutations relevant for diagnosis.","dc:creator":"Philips AK","dc:date":"2014","dc:title":"X-exome sequencing in Finnish families with intellectual disability--four novel mutations and two novel syndromic phenotypes."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24721225","rdfs:label":"V-1"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1,"dc:description":"not RNA experiment to confirm the impact"},{"id":"cggv:31487987-50a3-4dbc-ab6f-830035a8076f_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:90fce7ad-2ee6-49b6-a665-be6114954167","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"","firstTestingMethod":"Sanger sequencing","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:31487987-50a3-4dbc-ab6f-830035a8076f_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:8732ab6c-f0a2-413e-aa7d-cff1dfd208f6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021120.3(DLG3):c.1373C>G (p.Ser458Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29943"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15185169","type":"dc:BibliographicResource","dc:abstract":"We have identified truncating mutations in the human DLG3 (neuroendocrine dlg) gene in 4 of 329 families with moderate to severe X-linked mental retardation. DLG3 encodes synapse-associated protein 102 (SAP102), a member of the membrane-associated guanylate kinase protein family. Neuronal SAP102 is expressed during early brain development and is localized to the postsynaptic density of excitatory synapses. It is composed of three amino-terminal PDZ domains, an src homology domain, and a carboxyl-terminal guanylate kinase domain. The PDZ domains interact directly with the NR2 subunits of the NMDA glutamate receptor and with other proteins responsible for NMDA receptor localization, immobilization, and signaling. The mutations identified in this study all introduce premature stop codons within or before the third PDZ domain, and it is likely that this impairs the ability of SAP102 to interact with the NMDA receptor and/or other proteins involved in downstream NMDA receptor signaling pathways. NMDA receptors have been implicated in the induction of certain forms of synaptic plasticity, such as long-term potentiation and long-term depression, and these changes in synaptic efficacy have been proposed as neural mechanisms underlying memory and learning. The disruption of NMDA receptor targeting or signaling, as a result of the loss of SAP102, may lead to altered synaptic plasticity and may explain the intellectual impairment observed in individuals with DLG3 mutations.","dc:creator":"Tarpey P","dc:date":"2004","dc:title":"Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15185169","rdfs:label":"III-3"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1,"dc:description":"not genomic wide sequencing, not experimental evidence"},{"id":"cggv:29fca55b-9348-4ba1-a47e-0f993e44dca0_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:91c9caca-967a-44f9-8fcb-bf34aa5fe9a9","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:29fca55b-9348-4ba1-a47e-0f993e44dca0_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:94f15fbd-7770-48fd-b38a-ec746afbbf92","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021120.3(DLG3):c.1092dupC (p.Thr365Hisfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29942"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15185169"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15185169","rdfs:label":"II-5"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1,"dc:description":"not genomic wide sequencing,"},{"id":"cggv:dcc0089f-6b16-4136-ab9a-5c025fd2904d_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:88820c25-6a16-4e00-b8c6-2bb6de7700ff","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"X-Exome sequencing","firstTestingMethod":"Exome sequencing","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:dcc0089f-6b16-4136-ab9a-5c025fd2904d_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:f80ce947-51cc-4c0e-9ceb-5cd408526b86","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_006724625.2(DLG3):c.649C>T (p.Arg217Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA413492393"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25649377","type":"dc:BibliographicResource","dc:abstract":"X-linked intellectual disability (XLID) is a genetically heterogeneous disorder with more than 100 genes known to date. Most genes are responsible for a small proportion of patients only, which has hitherto hampered the systematic screening of large patient cohorts. We performed targeted enrichment and next-generation sequencing of 107 XLID genes in a cohort of 150 male patients. Hundred patients had sporadic intellectual disability, and 50 patients had a family history suggestive of XLID. We also analysed a sporadic female patient with severe ID and epilepsy because she had strongly skewed X-inactivation. Target enrichment and high parallel sequencing allowed a diagnostic coverage of >10 reads for ~96% of all coding bases of the XLID genes at a mean coverage of 124 reads. We found 18 pathogenic variants in 13 XLID genes (AP1S2, ATRX, CUL4B, DLG3, IQSEC2, KDM5C, MED12, OPHN1, SLC9A6, SMC1A, UBE2A, UPF3B and ZDHHC9) among the 150 male patients. Thirteen pathogenic variants were present in the group of 50 familial patients (26%), and 5 pathogenic variants among the 100 sporadic patients (5%). Systematic gene dosage analysis for low coverage exons detected one pathogenic hemizygous deletion. An IQSEC2 nonsense variant was detected in the female ID patient, providing further evidence for a role of this gene in encephalopathy in females. Skewed X-inactivation was more frequently observed in mothers with pathogenic variants compared with those without known X-linked defects. The mutation rate in the cohort of sporadic patients corroborates previous estimates of 5-10% for X-chromosomal defects in male ID patients.","dc:creator":"Tzschach A","dc:date":"2015","dc:title":"Next-generation sequencing in X-linked intellectual disability."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25649377","rdfs:label":"patient 15"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1,"dc:description":"not RNA/protein data"},{"id":"cggv:e2533281-dae9-4ac7-b930-ce89887a0f25_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:eca73063-e0a7-49c0-bfc5-a070fbe6af2f","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"","firstTestingMethod":"Sanger sequencing","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:e2533281-dae9-4ac7-b930-ce89887a0f25_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:9c2b4517-dc56-4e46-ad1d-89fa0782cd5e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"DLG3, IVS6DS, G-A, +5","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11518"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15185169"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15185169","rdfs:label":"III-1"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5,"dc:description":"not genomic wide sequencing\nbut with  cDNA analysis show del, Fig 2 A"},{"id":"cggv:f76785e1-ffa0-4604-9320-ebe5127ed4b0_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:4d7b2f42-74a2-4075-9dcb-5ef4bac1d6a3","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"X-exome sequencing of the index patient (III-8) revealed two novel variants, one in DLG3 and the other in ZBTB33 (Additional file1: Table S1). The ZBTB33 variant was excluded because it did not co-segregate with the phenotype. \nFor enrichment of genomic DNA from 11 index patients we used the Agilent SureSelect Human X-Chromosome Exome kit (Agilent, California, USA) and for three index patients (D299, D301, D303) we performed droplet-based multiplex PCR (7,367 amplicons, 757 genes, 1.54 Mb) similarly to the previously described study[13]. DNAs were sequenced on the Illumina GAII and HiSeq2000 platforms, respectively. For all samples coverage of at least 10X was reached for >86% of the targeted regions. Average sequencing depth ranged between 149â€“583. The sequence files were then aligned against the hg19 reference genome by SOAP2.21 with the default settings. Variants in the form of SNVs, indels and CNVs were called by an in house software package (Medical Re-sequencing Analysis Pipeline (MERAP), developed at the Max Planck Institute for Molecular Genetics, Berlin. All sequence variants were screened against publicly available databases (dbSNP138, 1000 Genomes project, Exome Variant Server (ESP6500) and the in-house database of the Max Planck Institute, Berlin) for annotating likely non-pathogenic and previously reported neutral variants. In addition, the OMIM catalogue and the Human Gene Mutation Database (HGMD) were used as a filter to identify all previously described pathogenic changes.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The affected males who presented with mild to moderate ID, normal growth, narrow thorax, molar hypoplasia, short up-slanting palpebral fissures, a high vaulted palate, and hypotonia. Daytime wetting has been a problem until adult age (Table 3). In addition to the aforementioned features the index patient (III-8) had an external strabismus in his right eye. Chromosomes (300bands), FRAXA, vacuolated lymphocytes, urinary metabolic screen, ophthalmology and hearing examinations showed normal results.","phenotypes":"obo:HP_0002342","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Exome sequencing","sex":"Male","variant":{"id":"cggv:f76785e1-ffa0-4604-9320-ebe5127ed4b0_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:065fcd7a-3ecf-4c39-8710-0326e721aade","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021120.3(DLG3):c.357+1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/127193"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24721225"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24721225","rdfs:label":"III-8"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1,"dc:description":"not experimental evidence show impact on RNA"},{"id":"cggv:b140a2ea-a84a-4f14-bcf5-8bc09019a4ec_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:e1e42e5b-bc28-4ad0-9f93-c62f4c3546be","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":61,"detectionMethod":"he 19 exons covering the coding regions of the human DLG3 gene and their flanking intronic sequences (MIM300189; GenBank accession number BC093864) were amplified by polymerase chain reaction (PCR) from genomic DNA of the patient. The fragments were first analysed by denaturing high-performance liquid chromatography (dHPLC) [5]. PCR products showing an abnormal dHPLC profile were then directly sequenced on an automated sequencer (ABI3100 PE Applied Biosystems Forster City, CA, USA) using the BigDye terminator chemistry. All variants were screened against a control panel of 160 X-chromosomes, to exclude polymorphisms.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"The proband, individual III-2 and his brother (III-3), aged 61 and 59 years, were born at term after a normal pregnancy, to healthy nonconsanguineous parents. Because of psychomotor delay, they were both sent to a school for special educational needs at the age of 4 and 6 years, respectively. At present, they live together in an institution for the mentally handicapped. The proband speaks in short sentences with a poorly articulated, unclear speech. He has a severe MR with a WISC full-scale IQ of 33. He also exhibits behavioural problems with abnormal sexual obsessive behaviour requiring pharmacological therapy.","previousTesting":true,"previousTestingDescription":"Standard karyotypes as well as FMR1 mutation analysis were negative in all affected individuals of the family.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:b140a2ea-a84a-4f14-bcf5-8bc09019a4ec_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:3b5deb55-85d0-472c-9f00-d43b0b4113d5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XM_006724625.2(DLG3):c.986-1G>A (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA413493675"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19795139","type":"dc:BibliographicResource","dc:abstract":"We have identified a novel splice site mutation (IVS6-1G > A) in the disc-large homolog 3 (DLG3) gene, encoding the synapse-associated protein 102 (SAP102) in one out of 300 families with moderate to severe non-syndromic mental retardation. SAP102 is a member of the neuronal membrane-associated guanylate kinase protein subfamily comprising SAP97, postsynaptic density (PSD)95, and PSD93, which interacts with methyl-D-aspartate receptor and associated protein complexes at the postsynaptic density of excitatory synapses. DLG3 is the first mental retardation gene directly linked to glutamate receptor signalling and trafficking, increasingly recognised as a central mechanism in the regulation of synaptic formation and plasticity in brain and cognitive development.","dc:creator":"Zanni G","dc:date":"2010","dc:title":"A novel mutation in the DLG3 gene encoding the synapse-associated protein 102 (SAP102) causes non-syndromic mental retardation."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19795139","rdfs:label":"III.2"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5,"dc:description":"RNA confirm skip exon 7, not genomic wide sequencing"}],"specifiedBy":"GeneValidityOverallAutosomalDominantNullVariantEvidenceCriteria","strengthScore":8},{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:fa5d4928-0e33-4043-92e0-72db68e0eb69_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:5d679bfe-4a5b-43c1-8c8a-aecec5e68511","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"","firstTestingMethod":"Sanger sequencing","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:fa5d4928-0e33-4043-92e0-72db68e0eb69_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:8dd8bfa1-4704-4958-89ba-a796f57274e4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"DLG3, IVS8DS, G-A, +1","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11519"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15185169"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15185169","rdfs:label":"III-1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2,"dc:description":"mother denovo, confirm RNA"}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:a09de439-1262-4e94-8629-f6ecf390ce0b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:2c25f83f-8fc3-4290-8713-94cf20928e38","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"We recently reported a secondary interaction between SAP102 and GluN2B, in addition to the PDZ interaction. Here, we identify two critical residues on GluN2B responsible for the non-PDZ binding to SAP102. Strikingly, either mutation of these critical residues or knockdown of endogenous SAP102 can rescue the defective surface expression and synaptic localization of PDZ binding-deficient GluN2B. These data reveal an unexpected, nonscaffolding role for SAP102 in the synaptic clearance of GluN2B-containing NMDARs.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23103165","type":"dc:BibliographicResource","dc:abstract":"Membrane-associated guanylate kinases (MAGUKs) are the major family of scaffolding proteins at the postsynaptic density. The PSD-MAGUK subfamily, which includes PSD-95, PSD-93, SAP97, and SAP102, is well accepted to be primarily involved in the synaptic anchoring of numerous proteins, including N-methyl-D-aspartate receptors (NMDARs). Notably, the synaptic targeting of NMDARs depends on the binding of the PDZ ligand on the GluN2B subunit to MAGUK PDZ domains, as disruption of this interaction dramatically decreases NMDAR surface and synaptic expression. We recently reported a secondary interaction between SAP102 and GluN2B, in addition to the PDZ interaction. Here, we identify two critical residues on GluN2B responsible for the non-PDZ binding to SAP102. Strikingly, either mutation of these critical residues or knockdown of endogenous SAP102 can rescue the defective surface expression and synaptic localization of PDZ binding-deficient GluN2B. These data reveal an unexpected, nonscaffolding role for SAP102 in the synaptic clearance of GluN2B-containing NMDARs.","dc:creator":"Chen BS","dc:date":"2012","dc:title":"SAP102 mediates synaptic clearance of NMDA receptors."},"rdfs:label":"IP and Y2H"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:b814c94d-97cf-40a8-8d77-ecf47ce0e17a","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:9ee64aee-5f3d-4d53-8f7a-11d41eb6ebf4","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"spatial learning associate with human intellectual ability","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17344405","type":"dc:BibliographicResource","dc:abstract":"Understanding the mechanisms whereby information encoded within patterns of action potentials is deciphered by neurons is central to cognitive psychology. The multiprotein complexes formed by NMDA receptors linked to synaptic membrane-associated guanylate kinase (MAGUK) proteins including synapse-associated protein 102 (SAP102) and other associated proteins are instrumental in these processes. Although humans with mutations in SAP102 show mental retardation, the physiological and biochemical mechanisms involved are unknown. Using SAP102 knock-out mice, we found specific impairments in synaptic plasticity induced by selective frequencies of stimulation that also required extracellular signal-regulated kinase signaling. This was paralleled by inflexibility and impairment in spatial learning. Improvement in spatial learning performance occurred with extra training despite continued use of a suboptimal search strategy, and, in a separate nonspatial task, the mutants again deployed a different strategy. Double-mutant analysis of postsynaptic density-95 and SAP102 mutants indicate overlapping and specific functions of the two MAGUKs. These in vivo data support the model that specific MAGUK proteins couple the NMDA receptor to distinct downstream signaling pathways. This provides a mechanism for discriminating patterns of synaptic activity that lead to long-lasting changes in synaptic strength as well as distinct aspects of cognition in the mammalian nervous system.","dc:creator":"Cuthbert PC","dc:date":"2007","dc:title":"Synapse-associated protein 102/dlgh3 couples the NMDA receptor to specific plasticity pathways and learning strategies."},"rdfs:label":"SAP102 null mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2,"dc:description":"the same KO mouse also used in 27466188"}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.5}],"evidenceStrength":"Definitive","sequence":442,"specifiedBy":"GeneValidityCriteria5","strengthScore":14.5,"subject":{"id":"cggv:f30149c6-d644-430b-8e4b-3c825cfdf333","type":"GeneValidityProposition","disease":"obo:MONDO_0019181","gene":"hgnc:2902","modeOfInheritance":"obo:HP_0001417"},"version":"1.0","dc:description":"The DLG3 gene has been associated with non-syndromic X-linked intellectual disability using the ClinGen Clinical Validity Framework as of 2018 Jul 26. This association was made using  case-level data only. At least 5 missense, 5 splicing, 2 small deletions, 3 small insertions have been reported in humans. DLG3 was first associated with this disease in humans as early as 2004 (Tarpey et al.). \nAND \nSummary of Case Level Data: 9 POINTS\nAssociation is seen in at least 9 probands in 5 publications (PMID: 15185169;19795139;24721225;25649377;2722290). Variants in this gene segregated with disease in 4-47 additional family members. \nFor STRONG/DEFINITIVE genes (if applicable):\nMore evidence is available in the literature, but the maximum score for genetic evidence and/or experimental evidence (12 pts.) has been reached. \nThe mechanism for disease is homozygous loss of function. (Tarpey et al 2004) \nOf note, this gene has also been implicated in Seizures and Epilepsy. These will be/have been assessed separately. \nEXPERIMENTAL EVIDENCE\nThis gene-disease association is supported by animal models (mouse KO), Protein interactions et al.\n","dc:isVersionOf":{"id":"cggv:e73a08f0-ff3a-4328-9020-89102296e405"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}